- Email: [email protected]
Correction to Lancet Diabetes Endocrinol 2014; published online Nov 14
Corrections
Correction to Lancet Diabetes Endocrinol 2014; published online Nov 14
Published Online June 4, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00166-7
Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol 2014; published online Nov 14. http://dx.doi.org/10.1016/S22138587(14)70212-8—This Review should have been a Personal View. This correction has been made to the online version as of June 4, 2015.
Correction to Lancet Diabetes Endocrinol 2015; 3: 503 Maruthappu M, Sood H, Obrien J, Keogh B. Diabetes prevention in England—Authors’ reply. Lancet Diabetes Endocrinol 2015; 3: 503—In this Correspondence, the second paragraph should have begun: “With specific regard to the National Diabetes Prevention Programme (NDPP), at least five major randomised controlled trials, done in China,2 Finland,3 the USA,4 Japan,5 and India6 have documented 30–60% reductions in type 2 diabetes incidence in adults with impaired glucose tolerance through implementation of intensive lifestyle change programmes”. This change has been made to the online version as of Oct 22, 2015.
www.thelancet.com/diabetes-endocrinology Vol 3 November 2015
e10
Correction to Lancet Diabetes Endocrinol 2014; published online Nov 14
Published Online June 4, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00166-7
Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol 2014; published online Nov 14. http://dx.doi.org/10.1016/S22138587(14)70212-8—This Review should have been a Personal View. This correction has been made to the online version as of June 4, 2015.
Correction to Lancet Diabetes Endocrinol 2015; 3: 503 Maruthappu M, Sood H, Obrien J, Keogh B. Diabetes prevention in England—Authors’ reply. Lancet Diabetes Endocrinol 2015; 3: 503—In this Correspondence, the second paragraph should have begun: “With specific regard to the National Diabetes Prevention Programme (NDPP), at least five major randomised controlled trials, done in China,2 Finland,3 the USA,4 Japan,5 and India6 have documented 30–60% reductions in type 2 diabetes incidence in adults with impaired glucose tolerance through implementation of intensive lifestyle change programmes”. This change has been made to the online version as of Oct 22, 2015.
www.thelancet.com/diabetes-endocrinology Vol 3 November 2015
e10